Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia.
Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, Goupille L, Boussaid I, Heiblig M, Boet E, Sahal A, Saland E, Santos JC, Armengol M, Fernández-Serrano M, Farge T, Cognet G, Simonetta F, Pignon C, Graffeuil A, Mazzotti C, Avet-Loiseau H, Delos O, Bertrand-Michel J, Chedru A, Dembitz V, Gallipoli P, Anstee NS, Loo S, Wei AH, Carroll M, Goubard A, Castellano R, Collette Y, Vergez F, Mansat-De Mas V, Bertoli S, Tavitian S, Picard M, Récher C, Bourges-Abella N, Granat F, Kosmider O, Sujobert P, Colsch B, Joffre C, Stuani L, Swinnen JV, Guillou H, Roué G, Hakim N, Dejean AS, Tsantoulis P, Larrue C, Bouscary D, Tamburini J, Sarry JE. Sabatier M, et al. Among authors: kosmider o. Cancer Discov. 2023 Jul 7;13(7):1720-1747. doi: 10.1158/2159-8290.CD-22-0411. Cancer Discov. 2023. PMID: 37012202
A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).
Sardnal V, Rouquette A, Kaltenbach S, Bally C, Chesnais V, Leschi C, Ades L, Santini V, Park S, Toma A, Fenaux P, Dreyfus F, Fontenay M, Kosmider O. Sardnal V, et al. Among authors: kosmider o. Leukemia. 2013 Jul;27(7):1610-3. doi: 10.1038/leu.2013.59. Epub 2013 Feb 26. Leukemia. 2013. PMID: 23434730 No abstract available.
Prognostic score including gene mutations in chronic myelomonocytic leukemia.
Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, Berthon C, Adès L, Fenaux P, Beyne-Rauzy O, Vey N, Braun T, Haferlach T, Dreyfus F, Cross NC, Preudhomme C, Bernard OA, Fontenay M, Vainchenker W, Schnittger S, Birnbaum D, Droin N, Solary E. Itzykson R, et al. Among authors: kosmider o. J Clin Oncol. 2013 Jul 1;31(19):2428-36. doi: 10.1200/JCO.2012.47.3314. Epub 2013 May 20. J Clin Oncol. 2013. PMID: 23690417
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).
Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, Viguié F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault-Berger M, Fenaux P, Mansat-De Mas V, Delabesse E, Guardiola P, Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA, Birnbaum D, Fontenay M; Groupe Francophone des Myélodysplasies. Kosmider O, et al. Blood. 2009 Oct 8;114(15):3285-91. doi: 10.1182/blood-2009-04-215814. Epub 2009 Aug 7. Blood. 2009. PMID: 19666869 Free article.
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C, Della Valle V, Couronné L, Scourzic L, Chesnais V, Guerci-Bresler A, Slama B, Beyne-Rauzy O, Schmidt-Tanguy A, Stamatoullas-Bastard A, Dreyfus F, Prébet T, de Botton S, Vey N, Morgan MA, Cross NC, Preudhomme C, Birnbaum D, Bernard OA, Fontenay M; Groupe Francophone des Myélodysplasies. Damm F, et al. Among authors: kosmider o. Blood. 2012 Apr 5;119(14):3211-8. doi: 10.1182/blood-2011-12-400994. Epub 2012 Feb 17. Blood. 2012. PMID: 22343920 Free article.
Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
Pérez B, Kosmider O, Cassinat B, Renneville A, Lachenaud J, Kaltenbach S, Bertrand Y, Baruchel A, Chomienne C, Fontenay M, Preudhomme C, Cavé H. Pérez B, et al. Among authors: kosmider o. Br J Haematol. 2010 Dec;151(5):460-8. doi: 10.1111/j.1365-2141.2010.08393.x. Epub 2010 Oct 19. Br J Haematol. 2010. PMID: 20955399 Free article.
Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias.
Couronné L, Lippert E, Andrieux J, Kosmider O, Radford-Weiss I, Penther D, Dastugue N, Mugneret F, Lafage M, Gachard N, Nadal N, Bernard OA, Nguyen-Khac F. Couronné L, et al. Among authors: kosmider o. Leukemia. 2010 Jan;24(1):201-3. doi: 10.1038/leu.2009.169. Epub 2009 Aug 27. Leukemia. 2010. PMID: 19710701 No abstract available.
Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations.
Nguyen-Khac F, Lesty C, Eclache V, Couronné L, Kosmider O, Andrieux J, Collonge-Rame MA, Penther D, Lafage M, Bilhou-Nabera C, Chapiro E, Mozziconacci MJ, Mugneret F, Gachard N, Nadal N, Lippert E, Struski S, Dastugue N, Cabrol C, Bernard OA; Groupe Francophone de Cytogénétique Hématologique. Nguyen-Khac F, et al. Among authors: kosmider o. Genes Chromosomes Cancer. 2010 Oct;49(10):919-27. doi: 10.1002/gcc.20802. Genes Chromosomes Cancer. 2010. PMID: 20629097
[Mutations in genes involved in splicing in human malignancies].
Damm F, Nguyen-Khac F, Kosmider O, Fontenay M, Bernard OA. Damm F, et al. Among authors: kosmider o. Med Sci (Paris). 2012 May;28(5):449-53. doi: 10.1051/medsci/2012285002. Epub 2012 May 30. Med Sci (Paris). 2012. PMID: 22642991 Free article. French. No abstract available.
147 results